Reported 23 days ago
Leerink Partners has reiterated a Buy rating for Akebia Therapeutics (NASDAQ:AKBA), setting a price target of $7. The analyst highlights the company's potential for growth, particularly with its product Vafseo, which addresses anemia in chronic kidney disease dialysis patients. The upcoming Phase 3 VALOR trial is expected to further enhance the company's market opportunities.
Source: YAHOO